中南医学科学杂志2025，Vol.53Issue(3)：442-445,4.DOI:10.15972/j.cnki.43-1509/r.2025.03.015
信迪利单抗联合放化疗治疗晚期NSCLC的近期疗效、安全性和预后观察
Observation on the short-term efficacy,safety and prognosis of sintilimab combined with chemoradiotherapy in the treatment of advanced non-small cell lung cancer
摘要
Abstract
Aim To observe the short-term efficacy,safety,and prognosis of sintilimab combined with chemoradiotherapy in the treatment of advanced non-small cell lung cancer(NSCLC).Methods Seventy-seven patients with advanced NSCLC were se-lected and divided into a combination group(39 cases,sintilimab combined with chemoradiotherapy)and a control group(38 cases,chemoradiotherapy alone).The efficacy,prognosis,safety,and changes in immune function were compared between the two groups.Results After treatment,the overall response rate(ORR)and disease control rate(DCR)in the combination group were higher than those in the control group(P＜0.05).The overall survival rate(OS)and progression-free survival rate(PFS)in the combination group were also higher than those in the control group(P＜0.05).After treatment,CD4+levels and the CD4+/CD8+ratio increased,while CD8+levels decreased in both groups,with more significant changes observed in the combination group compared to the control group(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Sintilimab combined with chemoradiotherapy demonstrates favorable efficacy,improved prognosis,and man-ageable adverse reactions in patients with advanced NSCLC.关键词
信迪利单抗/放化疗/晚期非小细胞肺癌/近期疗效/不良反应/预后Key words
sintilimab/chemoradiotherapy/advanced non-small cell lung cancer/short-term efficacy/adverse reactions/prognosis分类
医药卫生引用本文复制引用
曹新超,许艳辉,贾同磊,贺丽君,马平..信迪利单抗联合放化疗治疗晚期NSCLC的近期疗效、安全性和预后观察[J].中南医学科学杂志,2025,53(3):442-445,4.基金项目
河北省医学科学研究项目(20242172) （20242172）
